Oncology – Urological
Post-trial follow-up | Metastasis-directed therapy vs. observation in oligometastatic prostate cancer.
18 Oct, 2022 | 12:47h | UTCCommentary: Metastasis-Directed Therapy for Prostate Cancer Found Beneficial Long-Term – Cancer Therapy Advisor
Commentary on Twitter
🚀 #JCO #RapidCommunication: STOMP & ORIOLE show improved progression-free survival w metastsis driven therapy over observation in oligometastatic #ProstateCancer
🎯 Largest benefit for patients harboring a high-risk mutation #PCSM @matthewdeek @piet_ost https://t.co/OO8kcTVvFT pic.twitter.com/FqxGisz34F— Journal of Clinical Oncology (@JCO_ASCO) September 19, 2022
Single-arm phase 2 study | A less intensive treatment strategy may be effective for patients with stage IIA and stage IIB seminoma.
17 Oct, 2022 | 12:25h | UTCSingle-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: De-escalation Strategy in Seminoma: An Alternative Option? – Medscape (free registration required)
Commentary on Twitter
🚨🚨
SAKK 01/10 results are out!! 👇🏽Stage IIA/B testicular seminoma➡️
1️⃣cycle of carboplatin+involved node RT
116 pts, median FU 4.5yrs
3yr PFS 93.7%, 7 relapses, all successfully salvaged. Seminoma-specific surv 💯%
Generally well tolerated, gr3+tox chemo-related https://t.co/vI6ipafhZ8— Sophia Kamran, MD (@sophia_kamran) October 11, 2022
M-A | Addition of androgen receptor targeted agents to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer.
27 Sep, 2022 | 13:02h | UTC
Single-arm Phase 1b/2 study | Enfortumab Vedotin plus Pembrolizumab in previously untreated advanced urothelial cancer.
21 Sep, 2022 | 13:10h | UTC
RCT | Intensity-modulated radiotherapy vs. stereotactic body radiotherapy for prostate cancer.
19 Sep, 2022 | 12:31h | UTCIntensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
My first Tweetorial 🧵 2 year toxicity results of PACE B published here. Big thanks to the 🇬🇧🇨🇦 and🇮🇪collaborators and the 874 men with prostate cancer who made this trial possible https://t.co/mERz2ox8TM
— Alison Tree 💙 (@alison_tree) September 14, 2022
ASCO Rapid Recommendation | Systemic therapy update on 177Lutetium-PSMA-617 for metastatic castration-resistant prostate cancer.
19 Sep, 2022 | 12:31h | UTC
Cohort Study | Long-term outcomes among men undergoing active surveillance for prostate cancer.
15 Sep, 2022 | 13:11h | UTCInvited Commentary: Exploring the Long-term Outcomes of Active Surveillance Among Men With Prostate Cancer—Best for Whom? – JAMA Network Open
RCT | Rezvilutamide vs. Bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer.
11 Sep, 2022 | 22:52h | UTCCommentaries:
Treatment options for metastatic hormone-sensitive prostate cancer – The Lancet Oncology
Rezvilutamide benefits shown in metastatic hormone-sensitive prostate cancer – medwire News
Commentary on Twitter
In a preplanned interim analysis of the phase III CHART trial in pts with high-volume mHSPC, rezvilutamide +ADT improve PFS (HR 0.44, 95% CI 0.33–0·.8; P<0.0001) & OS (HR 0.58, 95% CI 0.44–0.77]; P=0.0001) compared with bicalutamide + ADT: https://t.co/42IVnDUxfH #PCSM #uroonc
— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022
RCT | Adjuvant atezolizumab fails to improve outcomes in patients with renal cell carcinoma at increased risk of recurrence following resection.
11 Sep, 2022 | 22:28h | UTCAdjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentaries:
Adjuvant atezolizumab falls short in renal cell carcinoma – Urology Times
IMmotion010 does not support adjuvant atezolizumab in intermediate-, high-risk RCC – medwire News
Commentary from the author on Twitter (thread – click for more)
Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) https://t.co/F5Y5HyNaxY pic.twitter.com/klAYWAQVwV
— Sumanta K. Pal, MD, FASCO (@montypal) September 10, 2022
30-month follow-up analysis of a RCT | Pembrolizumab vs. placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma.
5 Sep, 2022 | 14:20h | UTCInvited Commentary: Adjuvant immunotherapy for renal cell carcinoma – The Lancet Oncology
Original Article: Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma – New England Journal of Medicine
RCT | Telaglenastat failed to improve the efficacy of Cabozantinib in patients with advanced renal cell carcinoma.
5 Sep, 2022 | 14:19h | UTCEfficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary on Twitter
https://twitter.com/JAMAOnc/status/1565368902674178048
Phase 2 RCT | Adjuvant intravesical chemohyperthermia not better than passive chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer.
25 Aug, 2022 | 12:00h | UTC
Commentary on Twitter
No benefit of adjuvant intravesical hyperthermic chemo (CHT) for intermediate-risk non–muscle-invasive bladder cancer
🔸DFS @ 24 mo was 61% vs 60%
🔸Patients treated with CHT were less likely to complete their treatment @EUplatinum @OncoAlert @Uroweb https://t.co/q8lB2MxBFf pic.twitter.com/E8Ay5hirBb— Yüksel Ürün (@DrYukselUrun) August 22, 2022
Under a Creative Commons license
M-A | Androgen receptor signaling inhibitors in addition to Docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
24 Aug, 2022 | 13:58h | UTC
Phase 2 RCT | Biomarker-selected maintenance Poly ADP-Ribose Polymerase inhibition with Rucaparib following chemotherapy for metastatic urothelial carcinoma.
15 Aug, 2022 | 11:42h | UTC
Cohort Study | Association of gonadotropin-releasing hormone agonists for prostate cancer with cardiovascular disease risk and hypertension in men with diabetes.
11 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
Study showed men with #T2DM on GnRH for prostate cancer had a 53% higher risk of an increase in CVD risk score than those not on GnRH, suggesting the need to control cardiovascular disease risk factors in men with T2DM receiving GnRH. #OrigInvestigation https://t.co/3cJ10PpQGN
— JAMA Network Open (@JAMANetworkOpen) August 8, 2022
Guideline | Androgen deprivation therapy: adverse events and management strategies.
3 Aug, 2022 | 14:15h | UTC
Retrospective cohort study | Sequential Intravesical Gemcitabine and Docetaxel seem effective for high-risk BCG-naïve nonmuscle-invasive bladder cancer.
2 Aug, 2022 | 11:58h | UTC
Cohort Study | Assessment of second primary cancer risk among men receiving primary radiotherapy vs. surgery for the treatment of prostate cancer.
29 Jul, 2022 | 12:23h | UTC
Commentary on Twitter
In this cohort study of patients with localized prostate cancer, radiotherapy was associated with a small increase in the risk of developing a second primary cancer. https://t.co/YsrNo3FKwM
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Cohort Study | Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients.
28 Jul, 2022 | 13:13h | UTCNews Release: Hormone therapy for prostate cancer increases the risk of dying from cardiovascular disease – Taylor & Francis
Guidelines on the diagnosis and treatment of prostate cancer.
20 Jul, 2022 | 12:11h | UTCThe Swedish national guidelines on prostate cancer – Scandinavian Journal of Urology
Part 2: Recurrent, metastatic and castration resistant disease
Updates on enhanced recovery after surgery for radical cystectomy.
20 Jul, 2022 | 12:03h | UTCUpdates on enhanced recovery after surgery for radical cystectomy – Therapeutic Advances in Urology
Related:
Complete List of Enhanced Recovery After Surgery (ERAS) Society Guidelines
Guidelines on germline testing for urologic tumor syndromes.
15 Jul, 2022 | 12:49h | UTCGuidelines on Germline Testing for Urologic Tumor Syndromes – European Urology Focus
How to treat renal cell carcinoma: the current treatment landscape and cardiovascular toxicities.
14 Jul, 2022 | 12:35h | UTC
Genetic testing in prostate cancer management: considerations informing primary care.
13 Jul, 2022 | 11:25h | UTC
Single-arm Study | Extended focal ablation of localized prostate cancer with high-frequency irreversible electroporation.
11 Jul, 2022 | 11:56h | UTCExtended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation: A Nonrandomized Controlled Trial – JAMA Surgery (link to abstract – $ for full-text)
Commentary: Novel Focal Therapy Yields Low Rate of Serious Prostate Cancers — Trial’s 6-month rate of 6% was superior to historical control – MedPage Today (free registration required)
Commentary on Twitter
This single-arm objective performance criteria trial indicated excellent efficacy and safety profile of the second-generation high-frequency irreversible electroporation as primary treatment for localized prostate cancer. https://t.co/FheqcxJeA5
— JAMA Surgery (@JAMASurgery) July 7, 2022